Cargando...
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left‐Sided RAS/BRAF Wild‐Type Colorectal Cancer: Which “Side” Are You On?
This commentary focuses on the results of the study by Pietrantonio et al., which evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left‐sided RAS/BRAF wild‐type colorectal cancer and appears in this issue. Both FOLFOXIRI [flu...
Guardado en:
| Publicado en: | Oncologist |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018293/ https://ncbi.nlm.nih.gov/pubmed/33539032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13705 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|